US FDA Mulls Standards For Neurodiagnostic Tools
This article was originally published in Clinica
Medical devices to diagnose Alzheimer’s and other neurological or psychological problems hold a great deal of promise, but validating their benefits for patients remains a pressing concern.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.